SELLAS Life Sciences Group Inc. Common Stock (SLS)

About SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It h…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

13

Website

www.sellaslifesciences.com/

Fundamentals

1-day range

$13$14.29

Market cap

$2.18B

P/E (trailing)

—

P/E (forward)

-138.50

EPS (trailing)

$-0.23

Dividend yield

—

Beta

2.61

Avg. volume

8.92M

Dividend pay date

November 8, 2019

Forecasts

2 analyst ratings

SELLAS Life Sciences Group Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SLS

  SELLAS Life Sciences Group Inc. Common Stock

  $13.17

  ▼ 13.45%
  Market cap $2.18BP/E —
  $1.39$15.88
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.17BP/E —
  $7.48$18.57
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $2.22BP/E —
  $15.86$50.81
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.13BP/E —
  $2.87$9.75
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.23BP/E —
  $14.94$47.65
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $2.10BP/E 6.39
  $10.34$19.25
• HCM

  HUTCHMED (China) Limited American Depositary Shares

  $12.4

  ▼ 0.12%
  Market cap $2.06BP/E 4.74
  $15.57$28.8

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
  benzinga · 8/27/2026
• 10 Health Care Stocks Whale Activity In Today’s Session
  Benzinga · 8/21/2026
• ImmunityBio Expands Commercial Access For ANKTIVA Bladder And Lung Cancer Treatment To Saudi Arabia
  Benzinga · 8/19/2026
• This One Data Readout Could Make Or Break Sellas Life Sciences Group
  SeekingAlpha · 8/13/2026
• 10 Health Care Stocks With Whale Alerts In Today’s Session
  Benzinga · 8/12/2026
• SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
  Benzinga · 8/11/2026
• Stock Picks From Seeking Alpha's July 2026 New Analysts
  SeekingAlpha · 8/6/2026
• SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst
  SeekingAlpha · 8/2/2026

• Stergiou Angelos M. · June 16, 2026 · Grant

  1.06M

Institutional Ownership

March 31, 2026

Total shares held

66.74M

Total value held

$278.72M

Institutional holders

158